These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 25132752)

  • 21. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
    Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
    Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Helicobacter pylori-associated diseases].
    Gisbert JP
    Gastroenterol Hepatol; 2015 Sep; 38 Suppl 1():39-48. PubMed ID: 26520195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of
    Varga M; Drácz L; Kolbenheyer E; Varga F; Patai ÁV; Solymosi N; Patai Á
    Orv Hetil; 2019 Aug; 160(34):1340-1345. PubMed ID: 31423829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
    Gisbert JP; Barrio J; Modolell I; Molina-Infante J; Aisa AP; Castro-Fernández M; Rodrigo L; Cosme A; Gisbert JL; Fernández-Bermejo M; Marcos S; Marín AC; McNicholl AG
    Dig Dis Sci; 2015 Feb; 60(2):458-64. PubMed ID: 25236423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
    Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
    Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.
    Treiber G; Ammon S; Malfertheiner P; Klotz U
    Helicobacter; 2002 Aug; 7(4):225-31. PubMed ID: 12165029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
    Pan J; Shi Z; Lin D; Yang N; Meng F; Lin L; Jin Z; Zhou Q; Wu J; Zhang J; Li Y
    Front Med; 2020 Feb; 14(1):43-50. PubMed ID: 31907860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.
    Graham DY; Dore MP; Lu H
    Expert Rev Anti Infect Ther; 2018 Sep; 16(9):679-687. PubMed ID: 30102559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.
    Xie Y; Zhu Y; Zhou H; Lu ZF; Yang Z; Shu X; Guo XB; Fan HZ; Tang JH; Zeng XP; Wen JB; Li XQ; He XX; Ma JH; Liu DS; Huang CB; Xu NJ; Wang NR; Lu NH
    World J Gastroenterol; 2014 Aug; 20(32):11415-21. PubMed ID: 25170230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.
    Miftahussurur M; Yamaoka Y
    Molecules; 2015 Apr; 20(4):6068-92. PubMed ID: 25856059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication.
    Ozturk O; Doganay L; Colak Y; Yilmaz Enc F; Ulasoglu C; Ozdil K; Tuncer I
    Arab J Gastroenterol; 2017 Jun; 18(2):62-67. PubMed ID: 28601610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.
    Chen L; He J; Wang L; Ge Q; Chu H; Chen Y; Chen X; Long Y; Deng Y; He H; Li A; Chen S
    Clin Exp Med; 2018 Nov; 18(4):569-576. PubMed ID: 29876770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence.
    Kate V; Kalayarasan R; Ananthakrishnan N
    Drugs; 2013 Jun; 73(8):815-24. PubMed ID: 23625272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA.
    Alsamman MA; Vecchio EC; Shawwa K; Acosta-Gonzales G; Resnick MB; Moss SF
    Dig Dis Sci; 2019 Oct; 64(10):2893-2898. PubMed ID: 31187323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.
    Molina-Infante J; Gisbert JP
    World J Gastroenterol; 2014 Aug; 20(30):10338-47. PubMed ID: 25132750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of antibiotic-resistant
    Alihosseini S; Ghotaslou R; Heravi FS; Ahmadian Z; Leylabadlo HE
    J Chemother; 2020 Oct; 32(6):273-285. PubMed ID: 32657237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.